



Tufts Center for the Study of Drug Development

TUFTS UNIVERSITY

# Impact REPORT

ANALYSIS AND INSIGHT INTO CRITICAL DRUG DEVELOPMENT ISSUES

## Large pharma success rate for drugs entering clinical trials in 1993-04: 16%

*Share of licensed products in development portfolios peaked in 1999-01*

- Nearly three-quarters of the drugs in the portfolios of the top pharmaceutical firms that reached clinical testing from 1993-07 originated in and were developed by the firms.
- Of six specific broad therapeutic categories analyzed, oncologic/immunologic and central nervous system (CNS) had the greatest number of drug candidates entering clinical testing over the 1993-07 period.
- For the top 50 firms, the annual rate at which drugs enter clinical testing increased 31% from 1999-01 to 2002-07.
- Systemic anti-infectives had the highest clinical approval success rate for self-originated new drugs, with more than one-quarter of the drugs entering clinical testing during 1993-04 estimated to receive U.S. marketing approval.
- Less than 10% of cardiovascular and CNS drugs entering the clinical testing pipeline during 1993-04 are estimated to attain U.S. marketing approval.